Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sight Sciences (SGHT)
NASDAQ:SGHT
Holding SGHT?
Track your performance easily
SGHT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.68 - $8.45
Previous CloseN/A
Volume59.09K
Average Volume (3M)243.34K
Market Cap
$148.71M
Enterprise Value$233.87M
Total Cash (Recent Filing)$21.24M
Total Debt (Recent Filing)$13.38M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Mar 20, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding50,754,616
10 Day Avg. Volume290,791
30 Day Avg. Volume243,335
Standard Deviation0.29
R-Squared0.18
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.87
Price to Cash Flow (P/CF)102.70
P/FCF Ratio25.10
Enterprise Value/Market Cap1.57
Enterprise Value/Revenue2.94
Enterprise Value/Gross Profit3.38
Enterprise Value/Ebitda-5.31
Forecast
1Y Price Target
$4.13Price Target Upside35.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Sight Sciences News
PremiumCompany Announcements
Sight Sciences Enhances Executive Compensation for 2025
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSGHT currently trades at a 1.3x 2025E EV/Sales, which is -55% below the company's 3-year historical trading average of 2.9x, indicating potential for multiple expansion.
Market OpportunitiesSGHT's OMNI has a competitive edge in the ~$5B standalone glaucoma MIGS market.
Product AdoptionWith 1k surgeons already trained on TearCare, the market is primed for meaningful adoption as coverage wins are secured.
Bears Say
Financial PerformanceSGHT pre-announced softer 4Q sales of $18.9-$19.1M, behind Street estimates of $20.4M.
Market TrendsThe short-term uncertainty around the core OMNI+cataract business is expected to be a headwind to growth.
Regulatory ChallengesFive Medicare administrative contractors finalized LCDs restricting coverage for glaucoma procedures using multiple MIGS, causing an industry-wide headwind.
---
Ownership Overview
29.89% Insiders
5.49% Mutual Funds
9.19% Other Institutional Investors
49.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SGHT FAQ
What was Sight Sciences’s price range in the past 12 months?
Sight Sciences lowest stock price was $2.67 and its highest was $8.45 in the past 12 months.
What is Sight Sciences’s market cap?
Sight Sciences’s market cap is $148.71M.
When is Sight Sciences’s upcoming earnings report date?
Sight Sciences’s upcoming earnings report date is Mar 20, 2025 which is in 48 days.
How were Sight Sciences’s earnings last quarter?
Sight Sciences released its earnings results on Nov 07, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.208 by -$0.012.
Is Sight Sciences overvalued?
According to Wall Street analysts Sight Sciences’s price is currently Undervalued.
Does Sight Sciences pay dividends?
Sight Sciences does not currently pay dividends.
What is Sight Sciences’s EPS estimate?
Sight Sciences’s EPS estimate is -0.21.
How many shares outstanding does Sight Sciences have?
Sight Sciences has 50,754,616 shares outstanding.
What happened to Sight Sciences’s price movement after its last earnings report?
Sight Sciences reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.208. Following the earnings report the stock price went down -9.615%.
Which hedge fund is a major shareholder of Sight Sciences?
Currently, no hedge funds are holding shares in SGHT
---
Sight Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.13 (35.41% Upside)
$4.13 (35.41% Upside)
Hedge Fund Trend
Increased
By 6.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $174.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.92%
12-Months-Change
Fundamentals
Return on Equity
-45.36%
Trailing 12-Months
Asset Growth
-18.71%
Trailing 12-Months
Company Description
Sight Sciences
Sight Sciences Inc is a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease. The company's product portfolio features the OMNI Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and viscoelastic delivery. The company's non-surgical product portfolio consists of TearCare system which is commercially available for both ophthalmologists and optometrists.
---
SGHT Company Deck
---
SGHT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture, with some positive developments such as Medicare coverage confirmation and improved cash flow, but also significant challenges including revenue shortfalls and the impact of new LCDs on growth. The company's efforts to improve commercial execution and enhance organizational structures are positive steps forward, but the immediate financial challenges and market restrictions weigh heavily.Read More>---
SGHT Stock 12 Month Forecast
Average Price Target
$4.13
▲(35.41% Upside)
Technical Analysis
Best Analysts Covering SGHT
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
+5.14%
reiterated a buy rating 17 days ago
Copying Thomas Stephan's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of +5.14% per trade.
---